The AbbVie LUNA study showed atogepant reduced migraine days more than placebo during the perimenstrual period and met all ranked endpoints.
Browsing: Markets
The Tetra Tech buyback program gained another $500 million of authorization, lifting the total amount available for repurchases to $898 million.
The Signet price target was raised to $120 from $100 at Raymond James, whose analyst retained an Outperform rating after quarterly results.
The Enspryng FDA review received Priority Review for MOGAD after a Phase 3 study showed a clinically meaningful reduction in relapse risk.
Meta stock was upgraded to Overweight at JPMorgan, whose analyst raised the price target to $820 on emerging AI monetization opportunities.
The IBM quantum hub at ETH Zurich plans to install Switzerland’s first Quantum System Two and support research, startups and industrial users.
Nike stock was resumed at Underweight by Morgan Stanley, whose analyst set a $31 target and warned that earnings expectations may be too high.
The Palantir cybersecurity program will offer selected municipalities, utilities and infrastructure operators continuous autonomous testing.
The Independence Realty Trust merger with Centerspace will create an $8.1 billion apartment REIT with more than 44,000 units.
Chewy earnings showed 7.3% sales growth and a wider adjusted EBITDA margin, prompting the retailer to raise its full-year outlook.